Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria.
The relationship between soluble Klotho (s-Klotho) levels, fibroblast growth factor 23 (FGF23) levels, and albuminuria in patients with diabetic chronic kidney disease (CKD) remains unclear. A total of 109 patients with type 2 diabetes (mean age 61.63±9.77 years), at the outpatient clinic of the Antalya Research and Training Hospital Nephrology Unit between January and June 2014, as well as 32 healthy controls (mean age 49.53±7.32 years) were enrolled for this cross-sectional study. Patients were classified into three groups according to their urinary albumin creatinine ratio (UACR), normoalbuminuria (UACR<30 mg/g), microalbuminuria (UACR 30-300 mg/g), and macroalbuminuria (UACR>300 mg/g). The blood was analyzed for FGF23, s-Klotho, parathyroid hormone (PTH), P, Ca, creatinine, and 25-hydroxyvitamin D3 (25hD) levels. Creatinine, s-Klotho, FGF23, and PTH levels were significantly higher and 25hD levels were significantly lower in the patient group than in the healthy controls (p<0.001). Between the groups according to UACR, 1-way analysis of variance revealed statistically significant differences for creatinine (p<0.001), 25hD (p<0.001), PTH (p=0.002), Ca (p=0.002), and albumin levels (p<0.001). A statistically significant positive correlation was found between s-Klotho and FGF23 (r=0.768; p=0.001), and between FGF23 levels and UACR (r=0.768; p=0.001). In conclusion, the results of the present study suggest that s-Klotho levels are significantly elevated in patients with diabetes and s-Klotho levels decreased with increasing albumin excretion in our patients despite a reduction in estimated glomerular filtration rate.
Antalya Training and Research Hospital, Antalya, Turkey.
Ayca
A
Inci
Department of Nephrology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
Funda
F
Sari
Antalya Egitim ve Arastirma Hastanesi, Antalya, Turkey.
Melahat
M
Coban
Antalya Training and Research Hospital, Antalya, Turkey.
Refik
R
Olmaz
Antalya Training and Research Hospital, Antalya, Turkey.
Suleyman
S
Dolu
Antalya Training and Research Hospital, Antalya, Turkey.
Metin
M
Sarıkaya
Department of Biochemistry, Antalya Training and Research Hospital, Antalya, Turkey.
Necat
N
Yılmaz
D000419:Albuminuria / Q000150:complications*; D016022:Case-Control Studies; D003928:Diabetic Nephropathies / Q000097:blood* / Q000150:complications*; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D005966:Glucuronidase / Q000097:blood*; D006801:Humans; D000090265:Klotho Proteins; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000150:complications; D012995:Solubility
C000717427:FGF23 protein, human; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D005966:Glucuronidase; D000090265:Klotho Proteins
Diabetic Nephropathies; Kidney Failure, Chronic; Proteinuria